The best example until now has been non-small-cell lung cancer (NSCLC), in which MET exon 14 skipping mutations affecting the corresponding splicing sites and MET-GCNG/GA occur in 3–5% and 1–6% of cases, respectively [2,3,4,5]. Here, MET is linked to non-small cell lung carcinoma.